Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14–13/PrE0109)
Uložené v:
| Názov: | Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14–13/PrE0109) |
|---|---|
| Autori: | Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, Angela DeMichele, Paolo Tarantino, Evandro de Azambuja, Georg Pfeiler, Miguel Martin, Justin M. Balko, Zbigniew Nowecki, Marija Balic, Adam M. Brufsky, Arlene Chan, Patrick G. Morris, Tufia Haddad, Sibylle Loibl, Yuan Liu, Lidija Soelkner, Christian Fesl, Erica L. Mayer, Michael Gnant, on behalf of the PALLAS groups and investigators |
| Zdroj: | Breast Cancer Res Breast Cancer Research, Vol 26, Iss 1, Pp 1-10 (2024) |
| Informácie o vydavateľovi: | Springer Science and Business Media LLC, 2024. |
| Rok vydania: | 2024 |
| Predmety: | Endocrine therapy, Adult, Receptor, ErbB-2, Pyridines, Research, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Breast Neoplasms, Palbociclib, Middle Aged, Antibody–drug conjugates, Aged [MeSH], HER2-low, Receptor, ErbB-2/metabolism [MeSH], Breast cancer, Receptor, ErbB-2/genetics [MeSH], Neoplasm Staging [MeSH], Piperazines/therapeutic use [MeSH], Breast Neoplasms/mortality [MeSH], Breast Neoplasms/pathology [MeSH], Female [MeSH], Pyridines/therapeutic use [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Humans [MeSH], Breast Neoplasms/genetics [MeSH], Breast Neoplasms/drug therapy [MeSH], Breast Neoplasms/metabolism [MeSH], Middle Aged [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Biomarkers, Tumor/metabolism [MeSH], Prognosis [MeSH], Prognosis, Piperazines, Receptors, Estrogen, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Female, RC254-282, Aged, Neoplasm Staging |
| Popis: | Bidirectional crosstalk between HER2 and estrogen receptor (ER) pathways may influence outcomes and the efficacy of endocrine therapy (ET). Low HER2 expression levels (HER2-low) have emerged as a predictive biomarker in patients with breast cancer (BC).PALLAS is an open, international, phase 3 study evaluating the addition of palbociclib for 2 years to adjuvant ET in patients with stage II-III ER-positive/HER2-negative BC. To assess the impact of HER2 expression on patient outcomes in the phase III PALLAS trial, we analyzed (1) the association between rate of HER2-low with demographic and clinicopathological parameters, (2) the prognostic value of HER2-low status on invasive disease-free survival (iDFS), distant relapse-free survival (DRFS), and overall survival (OS) and (3) HER2 expression's value as a predictive biomarker of response to palbociclib. HER2-low was defined as HER2 immunohistochemistry (IHC) 1 + or IHC 2 + with negative in situ hybridization (ISH). All pathologic evaluation was performed locally. Prognostic and predictive power of HER2 were assessed with Cox models.From the original PALLAS intention-to-treat population (N = 5753), 5304 patients (92.2%) were included in this analysis. Among these, 2254 patients (42.5%) were classified as having HER2 IHC 0 (HER2-0), and 3050 (57.5%) as having HER2-low disease (1838 with IHC 1 + and 1212 with IHC 2 +). Median follow-up was 59.8 months. HER2-low prevalence varied significantly across 21 participating countries (range 16.7% to 75.6%; p |
| Druh dokumentu: | Article Other literature type |
| Jazyk: | English |
| ISSN: | 1465-542X |
| DOI: | 10.1186/s13058-024-01899-2 |
| Prístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/39375745 https://doaj.org/article/c4f4965043a847fba7a786c64cdbe554 https://repository.publisso.de/resource/frl:6500183 |
| Rights: | CC BY NC ND |
| Prístupové číslo: | edsair.doi.dedup.....7b125e4e02b83557647577c13480f4fe |
| Databáza: | OpenAIRE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Bidirectional crosstalk between HER2 and estrogen receptor (ER) pathways may influence outcomes and the efficacy of endocrine therapy (ET). Low HER2 expression levels (HER2-low) have emerged as a predictive biomarker in patients with breast cancer (BC).PALLAS is an open, international, phase 3 study evaluating the addition of palbociclib for 2 years to adjuvant ET in patients with stage II-III ER-positive/HER2-negative BC. To assess the impact of HER2 expression on patient outcomes in the phase III PALLAS trial, we analyzed (1) the association between rate of HER2-low with demographic and clinicopathological parameters, (2) the prognostic value of HER2-low status on invasive disease-free survival (iDFS), distant relapse-free survival (DRFS), and overall survival (OS) and (3) HER2 expression's value as a predictive biomarker of response to palbociclib. HER2-low was defined as HER2 immunohistochemistry (IHC) 1 + or IHC 2 + with negative in situ hybridization (ISH). All pathologic evaluation was performed locally. Prognostic and predictive power of HER2 were assessed with Cox models.From the original PALLAS intention-to-treat population (N = 5753), 5304 patients (92.2%) were included in this analysis. Among these, 2254 patients (42.5%) were classified as having HER2 IHC 0 (HER2-0), and 3050 (57.5%) as having HER2-low disease (1838 with IHC 1 + and 1212 with IHC 2 +). Median follow-up was 59.8 months. HER2-low prevalence varied significantly across 21 participating countries (range 16.7% to 75.6%; p |
|---|---|
| ISSN: | 1465542X |
| DOI: | 10.1186/s13058-024-01899-2 |